Related Experiment Video
Updated: Mar 24, 2026
07:00
A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene
Published on: April 1, 2019
10.5K
[Applied pharmacogenetic].
1Service de néphrologie, département hypertension artérielle, prévention et prise en charge des maladies rénales et cardiovasculaires, hôpital européen Georges-Pompidou, 20, rue Leblanc, 75015 Paris, France.
Nephrologie & Therapeutique
|March 15, 2016
Summary
Pharmacogenetics links genetic data to treatment selection, efficacy, and toxicity. Despite its potential, limited clinical use stems from a lack of outcome evidence and effective drug monitoring.
Area of Science:
- Pharmacology
- Genetics
- Clinical Medicine
Background:
- Pharmacokinetics connects genetic information with therapeutic strategies, aiding in treatment selection, efficacy, and toxicity prediction.
- Pharmacogenetics has historical applications in nephrology, such as predicting azathioprine-induced myelotoxicity.
- Despite established links between genetics and drug metabolism/transport, genetic testing is underutilized in clinical practice.
Purpose of the Study:
- To explore the reasons behind the limited clinical implementation of pharmacogenetic testing.
- To discuss the role of therapeutic drug monitoring in mitigating genotype-driven pharmacokinetic variability.
- To outline future directions for pharmacogenetics, emphasizing integrated treatment models.
Main Methods:
- Literature review on pharmacogenetics applications and clinical implementation challenges.
- Analysis of factors limiting the adoption of genetic tests in healthcare.
- Discussion of emerging pharmacogenetic models incorporating multiple genetic and clinical parameters.
Main Results:
- Clinical utility of pharmacogenetic tests is hindered by a lack of proven improved patient outcomes.
- Effective therapeutic drug monitoring can compensate for pharmacokinetic variations influenced by genetic factors.
- Current genetic tests have limited impact due to the complexity of drug response.
Conclusions:
- Future pharmacogenetics will involve sophisticated treatment models integrating patient characteristics, multiple gene polymorphisms, pharmacodynamics, and toxicity predictors.
- Overcoming implementation barriers requires demonstrating clear clinical benefits and developing comprehensive predictive models.
- Personalized medicine advancements depend on robust pharmacogenetic integration into routine clinical decision-making.
Related Concept Videos
01:29Pharmacogenetics and Pharmacogenomics: Overview
137
Pharmacogenetics and pharmacogenomics examine how genetic factors influence an individual's response to drugs. While pharmacogenetics focuses on the impact of specific genetic variants on drug effects, pharmacogenomics takes a broader approach, studying how genetic variation across populations contributes to differences in drug responses. These fields aim to explain why individuals may experience varying levels of efficacy or adverse reactions to the same medication.Variability in drug...
137
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
108
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
108
01:29Pharmacogenomics: Identification of New Drug Targets
76
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
76
01:27Pharmacogenetics of Drug Metabolism: Overview
106
Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
106
01:27Principles of Pharmacogenetics: Types of Genetic Variants
87
The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
87
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
66
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
66